Application of acyl cyanophosphorane methodology to the synthesis of protease inhibitors: Poststatin, eurystatin, phebestin, probestin and bestatin

Tetrahedron

Volumn 59, Issue 35, 2003, Pages 6771-6784

  Wasserman, Harry H ^a   Petersen, Anders K ^a   Xia, Mingde ^a  

^a YALE UNIVERSITY   (United States)

Author keywords

Acyl cyanophosphorane; Poststatin; keto amides

Indexed keywords

ACYL CYANOPHOSPHORANE; AMIDE; BESTATIN; EURYSTATIN; PHOSPHORANE DERIVATIVE; POSTSTATIN; PROBESTIN; PROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; DIASTEREOISOMER; DRUG SYNTHESIS; PRIORITY JOURNAL; REDUCTION; STEREOCHEMISTRY; TECHNIQUE;

EID: 0042158455     PISSN: 00404020     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0040-4020(03)00860-3     Document Type: Article

References (41)

1. Wasserman H.H., Ennis D.S., Power P.L., Ross M.J., Gomes B. J. Org. Chem. 58:1993;4785-4787.
2. Wasserman H.H., Ho W.-B. J. Org. Chem. 59:1994;4364-4366.
3. Wasserman H.H., Zhang R. Tetrahedron. 58:2002;6277-6283.
4. Fusetani N., Matsunaga S. Chem. Rev. 93:1993;1793-1806.
5. (a) Fusetani N., Matsunaga S., Matsumoto H., Takebayashi Y. J. Am. Chem. Soc. 112:1990;7053-7054
6. (b) Hagihara M., Schreiber S.L. J. Am. Chem. Soc. 114:1992;6570-6571.
7. Fusetani N., Sugawara T., Matsunaga S. J. Am. Chem. Soc. 113:1991;7811-7812.
8. Kobayashi J., Itagaki F., Shigemori H., Ishibashi M., Takahashi K., Ogura M., Nagasawa S., Nakamura T., Hirota H., Ohta T., Nozoe S. J. Am. Chem. Soc. 113:1991;7812-7813.
9. Gunasekera S.P., Pomponi S.A., McCarthy P.J. J. Nat. Prod. 57:1994;79-83.
10. Toda S., Kotake C., Tsuno T., Narita Y., Yamasaki T., Konishi M. J. Antibiot. 45:1992;1580-1586.
11. Orita M., Yasumuro K., Kokubo K., Shimizu M., Abe K., Tokunaga T., Kaniwa H. J. Antibiot. 48:1995;1430-1434.
12. Mierzwa R., King A., Conover M.A., Tozzi S., Puar M.S., Patel M., Coval S.J., Pomponi S.A. J. Nat. Prod. 57:1994;175-177.
13. Swersey J.C., Ireland C.M., Cornell L.M., Peterson R.W. J. Nat. Prod. 57:1994;842-845.
14. Casapullo A., Minale L., Zollo F., Lavayre J. J. Nat. Prod. 57:1994;1227-1233.
15. (a) Burkhart J.P., Peet N.P., Bey P. Tetrahedron Lett. 29:1988;3433-3436
16. (b) Angelastro M.R., Peet N.P., Bey P. J. Org. Chem. 54:1989;3913-3916
17. (c) Burkhart J.P., Peet N.P., Bey P. Tetrahedron Lett. 31:1990;1385-1388
18. (d) Peet N.P., Burkhart J.P., Angelastro M.R., Giroux E.L., Mehdi S., Bey P., Kolb M., Neises B., Schirlin D. J. Med. Chem. 33:1990;394-407
19. (e) Iwanowicz E.J., Lin J., Roberts D.G.M., Michel I.M., Seiler S.M. Biomed. Chem. Lett. 2:1992;1607-1612
20. (f) Edwards P.D., Meyer E.F. Jr., Vijayalakshmi J., Tuthill P.A., Andisik D.A., Gomes B., Strimpler A. J. Am. Chem. Soc. 114:1992;1854-1863
21. (g) Cutrona K.J., Sanderson P.E.J. Tetrahedron Lett. 37:1996;5045-5048.
22. (a) Aoyagi T., Nagai M., Ogawa K., Kojima F., Okada M., Ikeda T., Hamada M., Takeuchi T. J. Antibiot. 44:1991;949-955
23. (b) Nagai M., Ogawa K., Muraoka Y., Naganawa H., Aoyagi T., Takeuchi T. J. Antibiot. 44:1991;956-961
24. (c) Tsuda M., Muraoka Y., Nagai M., Aoyagi T., Takeuchi T. Pept. Chem. 1991;223-228
25. (d) Takeuchi, T.; Aoyagi, T.; Hamada, M.; Naganawa, H.; Ogawa, K.; Nagai, M.; Muraoka, Y.; Tsuda, M. US Patent 5, 359, 138, 1994.
26. (e) Tsuda M., Muraoka Y., Nagai M., Aoyagi T., Takeuchi T. J. Antibiot. 49:1996;281-286
27. (f) Tsuda M., Muraoka Y., Nagai M., Takeuchi T., Aoyagi T. J. Antibiot. 49:1996;287-291.
28. The earlier general route to α-keto amides from carboxylic acids followed the sequence shown below.
29. Wasserman H.H., Petersen A.K. Tetrahedron Lett. 38:1997;953-956. and references therein.
30. A side product in the deprotection of 8 was shown to be the pyrrolidin-3-one 9a formed most probably by the intramolecular addition of the free amino group to the nitrile (see Section 3.1.2).
31. The synthetic poststatin was identical in all respects to a sample kindly provided by Dr Y. Muraoka.
32. (a) Toda S., Obi Y., Numata K.-., Hamagishi Y., Tomita K., Komiyama N., Kotake C., Furumai T., Oki T. J. Antibiot. 45:1992;1573-1579
33. (b) Toda S., Kotake C., Tsuno T., Narita Y., Yamasaki T., Konishi M. J. Antibiot. 45:1992;1580-1586
34. (c) Suzuki K., Toda S., Furumai T., Fukagawa Y., Oki T. J. Antibiot. 47:1994;982-991.
35. Wasserman H.H., Petersen A.K. J. Org. Chem. 62:1997;8972-8973. and references therein.
36. (E)-6-Methyl-2-heptenoic acid ( 31 ) was prepared from 4-methyl-1-pentanol by oxidation to the corresponding aldehyde. Wittig olefination with (tert-butoxycarbonylmethylene)triphenylphosphorane afforded tert-butyl-(E)-6-methyl-2-heptenoate as a 95:5 mixture of geometric isomers. Deprotection with TFA followed by fractional distillation gave the isomerically pure (E)-acid 31.
37. 13C NMR spectra of all intermediates. Additional evidence was obtained from a 1:1 mixture of 22 and its alanine epimer prepared by equilibration with triethylamine. Cyclization, according to the protocol shown in Scheme 6, furnished 29 and its alanine epimer in a ratio of 1:1. This control experiment demonstrated unambiguously that the stereochemistry of 29 was intact.
38. Rappe C. Organic Syntheses. Vol. 53:1973;Wiley, New York.
39. Wasserman H.H., Xia M., Wang J., Petersen A.K., Jorgensen M. Tetrahedron Lett. 40:1999;6163-6166. and references therein.
40. We thank Dr Takaaki, Institute of Microbial Chemistry, Tokyo for samples of phebestin and probestin.
41. Still W.C., Kahn M., Mitra A. J. Org. Chem. 43:1978;2923-2925.